-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $220

Benzinga·02/11/2026 16:38:17
Listen to the news
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $205 to $220.